Global Antidiabetics Market is expected to reach USD
84.13 billion by 2020, according to a new study by Grand View Research, Inc.
Growing prevalence of diabetes is the primary driver of this market. Growth in
prevalence of disease causing lifestyle disorders such as irregular dietary
habits and obesity is also expected to boost product demand by triggering
incidence rates of target diseases. Future commercialization of products
currently in the pipeline and the presence of large untapped opportunities in the
emerging Asia Pacific and Latin American markets is expected to fuel future
market growth.
 |
Global antidiabetics market, by product, 2012 – 2020 (USD Billion)
|
Insulin was the most revenue generating segment and its
market was valued at over USD 20.0 billion in 2013. Insulin is also one of the
most lucrative segments of this market. Introduction of new products exhibiting
higher efficacy coupled with the presence of favorable government initiatives
are some factors attributing to its market attractiveness.
In depth research report on Antidiabetics
Market
Further
key findings from the study suggest:
·
Long
acting insulin was the leading product segment in 2013 and is expected to grow
at the CAGR of over 15.0% during the forecast period. The introduction of
advanced products, high prices associated with these products and the phasing out
of human insulin are some key factors attributing for its large share.
·
Rapid
uptake of newly approved DPP-4 inhibitors such as Januvia, Nesina and Onglyza
on account of their once daily dosage regimens and safety profiles catalyzed
the growth of this market.
·
North
America was the most matured antidiabetics market in 2013 accounting for over
43.0% of the market High market penetration of insulin and other antidiabetics
and the presence of sophisticated reimbursement framework are expected to drive
regional market growth.
·
Asia
Pacific is expected to present manufacturers with lucrative future growth
opportunities. Large presence of unmet patient needs and rapidly improving
healthcare infrastructure are some factors expected to drive market growth in
the region. The market is also expected to be driven by the introduction of
cheaper products made available by local manufacturers.
·
Some
key market players of antidiabetics include Sanofi Aventis, Takeda
Pharmaceuticals, Eli Lilly, Oramed Pharmaceuticals Inc., Merck & Co. Inc.,
Novo Nordisk, Bristol-Myers Squibb, Halozyme Therapeutics and Pfizer.
·
The
market is oligopolistic in nature with few players accounting for over 70% of
the market. Extensive R&D investments aimed at new product development and
entering new markets via government contracts are the key sustainability
strategies adopted by these organizations.
For the purpose of this study, Grand View Research has
segmented the global antidiabetics market on the basis of product and region:
Global Insulin Product Outlook
(Revenue, USD Million, 2012 - 2020)
·
Rapid
acting
·
Long
acting
·
Premixed
·
Premixed
analog
·
Short
acting
·
Intermediate
acting
Global Antidiabetics Product
Outlook (Revenue, USD Million, 2012 - 2020)
·
Alpha-glucosidase
inhibitors
·
Biguanides
·
Sulphonylureas
·
GLP-1
agonist
·
Meglitinides
·
DPP-4
inhibitors
·
SGLT
– 2
·
Thiazolodinediones
Antidiabetics Regional Outlook
(Revenue, USD Million, 2012 - 2020)
·
North
America
·
Europe
·
Asia
Pacific
·
RoW
Browse more research reports of this
category:
About
Grand View Research
Grand View Research, Inc. is a U.S. based market research
and consulting company, registered in the State of California and headquartered
in San Francisco. The company provides syndicated research reports, customized
research reports, and consulting services. To help clients make informed
business decisions, the company offers market intelligence studies ensuring
relevant and fact-based research across a range of industries including
technology, chemicals, materials, healthcare and energy.
For more market analysis reports,
please visit: http://www.grandviewresearch.com/
No comments:
Post a Comment